PCSK9基因多态性对冠心病患者使用瑞舒伐他汀调脂效果的影响  

Impact of PCSK9 gene polymorphism on effect of rosuvastatin on lipid regulation

作　　者：徐玲霞 李峰[1,2] 肖建强 师干伟[1,2] 俞磊 李丽 蔡高军[1,2] XU Ling-xia;LI Feng;XIAO Jian-qiang;SHI Gan-wei;YU Lei;LI Li;CAI Gao-jun(Department of Cardiology,Wujin Hospital Affiliated with Jiangsu University,Changzhou 213017,China;Department of Cardiology,The Wujin Clinical College of Xuzhou Medical University,Changzhou 213017,China)

机构地区：[1]江苏大学附属武进医院心内科,江苏常州213017 [2]徐州医科大学武进临床学院心内科,江苏常州213017

出　　处：《现代药物与临床》2019年第12期3782-3785,共4页Drugs & Clinic

基　　金：江苏省青年医学重点人才培养项目（QNRC2016310）;江苏大学临床医学科技发展基金项目（JLY2018094)

摘　　要：目的探讨前蛋白转化酶枯草杆菌溶菌素-9(PCSK9)基因E670G多态性是否影响冠心病患者瑞舒伐他汀调脂疗效。方法选取2012年9月-2017年7月在江苏大学附属武进医院治疗的134名冠心病患者,口服瑞舒伐他汀钙片10 mg,每晚1次,疗程1个月。采用PCR-LDR法检测PCSK9 E670G基因多态性,比较服药前后的血脂的变化情况。结果共134名冠心病患者完成血脂随访。治疗后,患者总胆固醇和低密度脂蛋白胆固醇水平均明显下降,而三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)水平无明显影响。134例患者中检出AA基因型121例,AG基因型13例。不同基因型服药前后的血脂变化情况与总体相似;但是不同基因型之间,瑞舒伐他汀的调脂疗效无明显差异。结论 PCSK9E670G基因多态性可能不影响瑞舒伐他汀的调脂疗效。Objective To explore the impact of PCSK9 gene E670 G polymorphism on the effect of rosuvastatin on lipid regulation in coronary heart disease patients. Methods Patients(134 cases) with coronary heart disease in Wujin Hospital Affiliated with Jiangsu University from September 2012 to July 2017 were selected, and were po administered with Rosuvastatin Calcium Tablets 10 mg every night, once daily for one month. PCR-LDR method was used to detect E670 G polymorphism. The changes of blood lipid were compared before and after taking medicine. Results Total of 134 coronary heart disease patients completed the follow-up. After treatment, the levels of total cholesterol and low-density lipoprotein cholesterol were significantly decreased, but the levels of TG and HDL-C were not significantly changed. Among 134 patients, 121 were AA genotype and 13 were AG genotype. The changes of lipid levels before and after therapy in different genotype groups were similar to the overall. However, the effects of rosuvastatin on lipid regulation were not significant difference in different genotype groups. Conclusion PCSK9 E670 G polymorphism might not affect the lipid-mediated effect of rosuvastatin in coronary heart disease patients.

关 键 词：冠心病 前蛋白转化酶枯草杆菌溶菌素-9(PCSK9) 瑞舒伐他汀 血脂 

分 类 号：R972[医药卫生—药品]